Wall Street expects a year-over-year decline in earnings on higher revenues when Johnson & Johnson (JNJ) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on October 15, 2024, might help the stock move higher if these key numbers are better ...

Johnson & Johnson (JNJ, Financial) has announced the termination of its phase 2 trial for the TAR-200 therapy aimed at treating patients with muscle-invasive bladder cancer (MIBC). The decision followed an interim analysis from the SunRISe-2 study, which indicated no advantage over existing chemo-radiation treatments.Despite this setback, the company remains committed to seeking FDA approval by early 2025 for TAR-200 as a monotherapy for non-muscle invasive bladder cancer (NMIBC). Johnson & Johnson expresse ...

Johnson & Johnson (JNJ) will report its third-quarter earnings on Oct. 15. The Zacks Consensus Estimate for sales and earnings is pegged at $22.19 billion and $2.19 per share, respectively. The Zacks Consensus Estimate for JNJ’s earnings has declined from $10.07 per share to $10.00 per share for 2024 and from $10.63 per share to $10.62 per share for 2025 over the past 60 days.JNJ Estimate MovementImage Source: Zacks Investment ResearchJNJ's Earnings Surprise HistoryThe healthcare bellwether’s performance ha ...

Johnson & Johnson (JNJ) announced that it has discontinued the phase II field study, which evaluated the company’s investigational antiviral candidate mosnodenvir (formerly JNJ-1802) for the prevention of dengue virus in patients aged between 18 years and 65 years.JNJ decided to stop this study (NCT05201794) as part of the strategic reprioritization of its Communicable Diseases research and development (R&D) portfolio.Year to date, shares of JNJ have risen 2.3% compared with the industry’s growth of 18.5%.I ...

While some investors relish the thrill of high-growth ventures with the potential for significant returns, others prioritize capital preservation and seek out investments that offer security and stability. This approach, known as risk aversion, is a core concept for investors seeking to minimize portfolio volatility and protect their principal investment. Get stock market alerts:Risk-Aversion and Risk-Averse StocksRisk-averse investors prioritize investments with lower potential returns and lower potential ...

These storied companies have a lot to offer different investors.Income stocks get their name because they provide dividend payments to your portfolio, expanding your returns and investment capital over time. Not only can income stocks boost your overall return on investment, but they can also be an excellent way to diversify the types of stocks you keep in your portfolio.If you're looking for income stocks to buy right now, here are two well-known names to consider for your list of potential investments.1. ...

The most recent trading session ended with Johnson & Johnson (JNJ) standing at $160.50, reflecting a -0.42% shift from the previouse trading day's closing. This move lagged the S&P 500's daily loss of 0.17%. At the same time, the Dow lost 0.44%, and the tech-heavy Nasdaq lost 0.04%.The world's biggest maker of health care products's stock has dropped by 3.7% in the past month, exceeding the Medical sector's loss of 3.8% and lagging the S&P 500's gain of 1.25%.The investment community will be paying close at ...

Results from CEPHEUS study highlight DARZALEX FASPRO® quadruplet regimen as a potential standard of care in newly diagnosed patients regardless of transplant eligibilityNew indication would be the first FDA-approved treatment regimen for newly diagnosed multiple myeloma based on a study with MRD-negativity as the primary endpoint RARITAN, N.J., Sept. 30, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food an ...

The new full visual range IOL*1 delivers exceptional distance vision2 and 14% smaller readable print size vs PanOptix3 †.93% of patients become free from glasses at all distances.#4 ‡TECNIS Odyssey IOL offers higher tolerance to residual refractive errors, enabling surgeons to deliver consistent and reliable patient outcomes.5¶JACKSONVILLE, Fla., Sept. 30, 2024 /PRNewswire/ -- Johnson & Johnson§, a global leader in eye health, has announced it's expanding the roll-out of its latest advancement in presbyopia ...

45 percent reduction in risk of death achieved with CARVYKTI® after three-year follow-up in landmark CARTITUDE-4 study  Data featured in a late-breaking oral presentation at the 2024 International Myeloma Society Annual MeetingRIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today long-term results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI® (ciltacabtagene autoleucel) significantly extended overall survival (OS) in patients with relapsed ...